Distress
Biomerica (BMRA) 10-K carries going-concern doubt with $1,308,000 in cash
Biomerica, Inc.'s annual report for the year ended May 31, 2026 includes a going-concern explanatory paragraph. Cash was $1,308,000 at May 31, 2026, down from $2,399,000 a year earlier.

Biomerica, Inc. (Nasdaq: BMRA) filed its Form 10-K for the fiscal year ended May 31, 2026 on August 31, 2026. The independent auditor's report includes an explanatory paragraph regarding substantial doubt about the company's ability to continue as a going concern. Cash and cash equivalents were $1,308,000 at May 31, 2026, against $2,399,000 at May 31, 2025. Working capital was $1,535,000, against $3,135,000 a year earlier.
Why is this important: An explanatory paragraph in the auditor's report is the auditor's formal flag on whether the company can keep operating without new money. For holders and lenders, the question is whether the cash on hand and the August 2026 placement can carry the company to its next financing on terms the filing does not yet describe.
Zackary S. Irani is the chief executive officer. The 10-K says that on August 27, 2026 the board appointed Xiaoxuan Qu as principal financial officer and principal accounting officer. Until a Chief Financial Officer is appointed, she may, with the approval of the chief executive officer, execute documents that would ordinarily be signed by a CFO. In our view, a company with a going-concern paragraph, no named chief financial officer and a placement bought in part by its own directors and executive officers has a thin bench for the work ahead.
What the auditor flagged
The 10-K says that the company's current level of cash and cash equivalents is not sufficient to meet its operating plans for the next 12 months, raising substantial doubt about its ability to continue as a going concern. The company says its ability to continue depends on obtaining additional financing, achieving further operating efficiencies, increasing sales, reducing costs and ultimately generating profitable operations. The filing adds that there is no assurance the company will secure the necessary capital on favorable terms, achieve sufficient revenue growth or implement adequate cost reductions.
Net sales fell from approximately $5,311,000 in fiscal 2025 to approximately $4,453,000 in fiscal 2026. The 10-K ties part of that decline to distributor ordering patterns and the timing of international shipments. The decrease in cash during fiscal 2026 primarily reflects approximately $3,400,000 of cash used in operating activities. Proceeds from sales of common stock under the 2024 ATM Offering and $500,000 received under a secured promissory note partly offset that outflow.
The finance team and the August placement
The board appointed Xiaoxuan Qu, age 33, as principal financial officer and principal accounting officer. The 10-K says she has been Vice President of Finance since January 2026, joined the company in June 2023 and was appointed Corporate Controller in January 2024. The board also authorized her to sign on the company's behalf all filings and reports to be submitted to the SEC. The Form 8-K filed August 26, 2026 reports a private placement of 1,393,705 shares at $1.60 a share, for aggregate gross proceeds of approximately $2.23 million. The purchasers included B. Riley Principal Capital, LLC and certain members of the board and executive officers.
Products, spending and what comes next
The 10-K says the company's research and development efforts led to FDA 510(k) clearance of hp+detect, a diagnostic test for Helicobacter pylori. It describes inFoods IBS as moving toward commercialization. Research and development expenses were approximately $788,000 in fiscal 2026, against $1,023,000 a year earlier, and the filing ties the drop partly to hp+detect moving from development to commercialization. The company says it intends to pursue inFoods applications in Functional Dyspepsia, Crohn's Disease, Ulcerative Colitis and other conditions. The 10-K also says current cash is insufficient for the next twelve months, so those applications depend on financing the filing does not yet describe.
The Form 10-Q filed April 13, 2026 described the same doubt before this report. It reported cash and cash equivalents of approximately $1,336,000 at February 28, 2026, and an accumulated deficit of approximately $55,798,000. The 10-K reports an accumulated deficit of approximately $56,943,000 at May 31, 2026. A 10-K/A filed September 28, 2026 amends only Part III and contains no financial statements.
Investor Chat
Loading posts…
aibio